Gastro-esophageal Junction Cancer Clinical Trial
Official title:
An Open-label, Single-arm, Single-center, Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo®) in Subjects With Advanced or Recurrent Gastric Cancer
This study was planned to evaluate the efficacy and safety of combination therapy of Immuncell-LC and nivolumab in patients with relapsed or advanced gastric adenocarcinoma or gastro-esophageal junction cancer.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00215514 -
Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
|
Phase 0 | |
Completed |
NCT00716157 -
Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation
|
N/A | |
Recruiting |
NCT06005493 -
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT01044511 -
Quality of Life With Esophageal Stent Trial
|
N/A | |
Completed |
NCT01077999 -
Chemoradiation and Panitumumab for Esophageal Cancer
|
Phase 2 | |
Completed |
NCT02359968 -
PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer
|
Phase 2 | |
Completed |
NCT01084330 -
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer
|
Phase 2 |